Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Accounts Payables (2022 - 2025)

Taysha Gene Therapies' Accounts Payables history spans 4 years, with the latest figure at $5.4 million for Q3 2025.

  • For Q3 2025, Accounts Payables rose 10.26% year-over-year to $5.4 million; the TTM value through Sep 2025 reached $5.4 million, up 10.26%, while the annual FY2024 figure was $3.6 million, 43.58% down from the prior year.
  • Accounts Payables for Q3 2025 was $5.4 million at Taysha Gene Therapies, down from $7.7 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $24.0 million in Q2 2022 and bottomed at $3.6 million in Q4 2024.
  • The 4-year median for Accounts Payables is $8.7 million (2024), against an average of $10.1 million.
  • The largest annual shift saw Accounts Payables crashed 59.08% in 2023 before it grew 15.31% in 2024.
  • A 4-year view of Accounts Payables shows it stood at $10.9 million in 2022, then tumbled by 41.84% to $6.4 million in 2023, then plummeted by 43.58% to $3.6 million in 2024, then skyrocketed by 51.39% to $5.4 million in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Accounts Payables are $5.4 million (Q3 2025), $7.7 million (Q2 2025), and $4.3 million (Q1 2025).